How have PPCB shares performed in 2024?

Propanc Biopharma's stock was trading at $0.0120 at the start of the year. Since then, PPCB stock has decreased by 88.3% and is now trading at $0.0014. View the best growth stocks for 2024 here .

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma, Inc. (OTCMKTS:PPCB) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.03) earnings per share (EPS) for the quarter.

When did Propanc Biopharma's stock split?

Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR) , Cronos Group (CRON) , CRISPR Therapeutics (CRSP) , Petroteq Energy (PQEFF) , Xerox (XRX) , Aurora Cannabis (ACBFF) , Amgen (AMGN) , Amarin (AMRN) and Aphria (APHQF) .

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PPCB

Propanc Biopharma (PPCB) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free PPCB Stock Alerts

$0.0014

0.00 (0.00%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.0013
▼
$0.0015
50-Day Range: N/A
52-Week Range: $0.00
▼
$0.26

Volume: 4.44 million shs
Average Volume: 3.26 million shs
Market Capitalization: $73,003.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Propanc Biopharma alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Propanc Biopharma Stock (OTCMKTS:PPCB)

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

PPCB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PPCB Stock News Headlines

April 16, 2024 | finance.yahoo.com

Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office

April 10, 2024 | stockhouse.com

Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 8, 2024 | finance.yahoo.com

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

February 22, 2024 | finance.yahoo.com

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

January 16, 2024 | finance.yahoo.com

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

December 18, 2023 | finance.yahoo.com

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

December 13, 2023 | finance.yahoo.com

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

December 12, 2023 | finance.yahoo.com

James Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDaily

November 7, 2023 | finanznachrichten.de

Propanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

November 7, 2023 | finance.yahoo.com

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

August 15, 2023 | finance.yahoo.com

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

July 26, 2023 | finance.yahoo.com

Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030

July 13, 2023 | finance.yahoo.com

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

July 5, 2023 | finance.yahoo.com

Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

June 30, 2023 | sg.finance.yahoo.com

PPCB - Propanc Biopharma, Inc.

June 28, 2023 | finance.yahoo.com

PROPANC BIOPHARMA INC (PPCB) stock forecast and price target

May 25, 2023 | finance.yahoo.com

Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe

May 23, 2023 | finance.yahoo.com

Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America

May 23, 2023 | finance.yahoo.com

Propanc Biopharma Announces Reverse Stock Split

March 28, 2023 | finance.yahoo.com

Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

March 16, 2023 | finance.yahoo.com

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

March 14, 2023 | benzinga.com

Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions

February 23, 2023 | seekingalpha.com

PPCB Propanc Biopharma, Inc.

January 11, 2023 | finance.yahoo.com

Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

December 17, 2022 | finanznachrichten.de

Propanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

See More Headlines

Receive PPCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/18/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:PPCB
CUSIP: N/A
CIK: 1517681
Web: www.propanc.com
Phone: (139) 882-0780
Fax: 61 03 9882 9969
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,660,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -1,592.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.06
Quick Ratio: 0.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.52) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 52,145,000
Free Float: 51,206,000
Market Cap: $73,003.00
Optionable: Not Optionable
Beta: 1.74

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. James Nathanielsz (Age 50)
Executive Chairman, CEO, CFO, Treasurer & Secretary
Comp: $430.28k
Dr. Julian Norman Kenyon ChB (Age 76)
M.D., MB, Chief Scientific Officer, CTO & Director
Comp: $35.99k
Prof. Klaus Kutz
Chief Medical Officer & Member of Scientific Advisory Board

Key Competitors

View All Competitors

PPCB Stock Analysis - Frequently Asked Questions

How have PPCB shares performed in 2024?: Propanc Biopharma's stock was trading at $0.0120 at the start of the year. Since then, PPCB stock has decreased by 88.3% and is now trading at $0.0014.
View the best growth stocks for 2024 here.
How were Propanc Biopharma's earnings last quarter?: Propanc Biopharma, Inc. (OTCMKTS:PPCB) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.03) earnings per share (EPS) for the quarter.
When did Propanc Biopharma's stock split?: Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of Propanc Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF).
How do I buy shares of Propanc Biopharma?: Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PPCB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Propanc Biopharma (PPCB) Stock Price, News & Analysis

About Propanc Biopharma Stock (OTCMKTS:PPCB)

PPCB Stock Price History

PPCB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PPCB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info